comparison of glp 1 drugs New for Weight Loss What Plan Sponsors Need to Know Metabolic Axis GLP-1-based therapies: current knowledge of
Description
doi: 10.1016/0006-8993(92)90432-9
Cardiovascular actions of incretin-based therapies
January 2026: Amgen completed Phase 3 enrollment for MariTide (AMG 133) in the MARITIME-Obesity trial, with interim efficacy data expected in Q3 2026 that will position the monthly injection GLP-1/GIP antagonist as a once-monthly obesity treatment alternative
In a genetic preclinical study, embryonic GIPR knockout mice fed a high-fat diet were protected from obesity, supporting the role of GIPR antagonism as a method to promote weight loss and prevent weight gain (67)
Together, these pathways make retatrutide one of the most promising future therapies for cardiometabolic health
